Sio Gene Therapies Inc (SIOX)


Stock Price Forecast

April 20, 2023


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Sio Gene Therapies Inc chart...

About the Company

Sio Gene Therapies combines cutting-edge science with bold imagination to develop genetic medicines that aim to radically improve the lives of patients. Its current pipeline of clinical-stage candidates includes the first potentially curative AAV-based gene therapies for GM1 gangliosidosis and Tay-Sachs/Sandhoff diseases, which are rare and uniformly fatal pediatric conditions caused by single gene deficiencies. The company is also expanding the reach of gene therapy to highly prevalent conditions such as Parkinson's disease, which affects millions of patients globally. Led by an experienced team of gene therapy development experts, and supported by collaborations with premier academic, industry and patient advocacy organizations, Sio is focused on accelerating its candidates through clinical trials to liberate patients with debilitating diseases through the transformational power of gene therapies.

CEO

Pavan Cheruvu

Exchange

OTC MARKETS

Website

www.axovant.com

$M

Total Revenue

42

Employees

$30M

Market Capitalization

-0.79

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $SIOX News

Sio Gene Therapies Inc. (SIOX)

3y ago, source: Nasdaq

Call and put options are quoted in a table called a chain sheet. The chain sheet shows the price, volume and open interest for each option strike price and expiration month. Nasdaq provides call ...

Taysha Gene Therapies, Inc.

1y ago, source: CNN

Taysha Gene Therapies, Inc.is a patient-centric, clinical-stage gene therapy company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies ...

Megatrends: Gene Therapy and Editing

14h ago, source: U.S. News & World Report

Investors often like to be on the cutting edge of new developments, and it doesn't get much more cutting edge than gene therapy and editing. The ability to make changes to a person's DNA – the ...

Positive Clinical Trials Bolster Buy Rating for Taysha Gene Therapies

8d ago, source: Business Insider

Taysha Gene Therapies (TSHA) Company Description: Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and ...

ONCT Oncternal Therapeutics, Inc.

6d ago, source: Seeking Alpha

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company’s clinical ...

Taysha Gene Therapies, Inc.: Taysha Gene Therapies Provides Update on Deprioritized Pipeline Programs

1mon ago, source: Finanznachrichten

Zeit Aktuelle Nachrichten Fr Taysha Gene Therapies, Inc.: Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) DALLAS, March 01, 2024 (GLOBE NEWSWIRE) -- Taysha ...

Taysha Gene Therapies, Inc.: Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

2mon ago, source: Finanznachrichten

DALLAS, March 01, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for ...

Sio Gene Therapies Inc. (SIOX)

3y ago, source: Nasdaq

*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green highlights the top performing ETF by % change in the past ...

Taysha Gene Therapies Inc.

3y ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Sio Gene Therapies Inc (SIOX)

10mon ago, source: Investing

Investing.com – U.S. equities were higher at the close on Thursday, as gains in the Technology, Oil & Gas and Consumer Services sectors propelled shares higher. At the close in... Pre-Open Stock ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...